Veriheal

AUGUST 7, 2022

New data published in the Journal of Cannabis Research claims that almost one in two authorized medical cannabis patients in Canada managed to either completely stop or reduce their intake of controlled substances, such as alcohol and opioids , by using cannabis. As of 2020, the market was worth CAD $2.6 billion (USD $2 billion).

Consumption 109

Consumption Patients Research and Development Data 109

The Cannigma

FEBRUARY 2, 2021

In a new survey of German patients with Parkinson’s disease, 8% of patients reported using cannabis products. However, the survey also revealed that, among the Parkinson’s disease patients , there was a noticeable knowledge gap concerning the different methods of consumption available and the individual effects of THC and CBD.

Patients 87

Patients Clinical Trials Research and Development Treatment 87

Cannabis Law Report

DECEMBER 2, 2021

The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021. Over 70% of these patients face one or more debilitating symptoms, including anxiety, depression, and agitation (Mendez, 2021).

Clinical Trials 52

Clinical Trials Data Patients THC 52

Cannabis Law Report

MAY 18, 2022

Observational Data Collected On Long-term Consumption of Oral C BD Shows No Correlation To Safety Issues Raised by FDA. Their participation strengthened the statistical reliability of both the liver safety results and achieved statistical relevance for both sleep and testosterone results.

Safety 52

Safety Hemp Research and Development Data 52

Cannabis Law Report

DECEMBER 7, 2021

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. Systematic review and meta-analysis were performed to examine the efficacy and safety of MCs treatment among children.

Safety 52

Safety Cannabinoids Events Data 52

Cannabis Law Report

JULY 7, 2021

New data shows MYMD-1 has key differentiators and capabilities compared to existing TNF inhibitor drugs. Data also demonstrated that none of the biological drugs selected for the comparison study proved to be anti-proliferative to any of the primary cell types assessed. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc.

Pharmaceutical 105

Pharmaceutical Data Clinical Trials Research and Development 105

Cannabis Law Report

MAY 18, 2022

NEW STUDY DEMONSTRATES CBD’S STRONG SAFETY PROFILE , AMPLIFIES CALLS FOR FDA REGULATION. Observational Data Collected On Long-term Consumption of Oral C BD Shows No Correlation To Safety Issues Raised by FDA. The second cohort included an additional 222 individuals taking CBD produced by an additional five companies.

Safety 52

Safety Hemp Research and Development Data 52

TheAnswerPage

JANUARY 11, 2022

Are you able to answer your patients’ medical marijuana questions? In fact, from pediatricians to geriatricians, I cannot think of any medical practitioner that does not need to be well informed about the endocannabinoid system and cannabis-based therapeutics. million medical marijuana patients nationwide.

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

JUNE 7, 2021

The Data and Safety Monitoring Committee (“DSMC”) for IGC’s clinical trial, having reviewed the data obtained through Cohort 1 and Cohort 2, recommended progressing to Cohort 3, which consists of administering three doses per day. This Phase 1 trial is currently testing IGC-AD1 for safety. Claudia Grimaldi. info@igcinc.us

Clinical Trials 105

Clinical Trials Patients THC Safety 105

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Veriheal

MAY 30, 2023

A new 2023 study published in BMJ Supportive & Palliative Care suggests that cannabis could be the answer millions of cancer patients have been looking for. of patients experience pain after curative treatment, while 66.4% of patients with advanced or metastatic cancer suffer from pain. Interestingly, 72.5%

Medicine 98

Medicine Treatment Patients Data 98

Cannabis Law Report

JUNE 1, 2021

The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. billion, servicing nearly 340,000 active patients.

Clinical Trials 89

Clinical Trials Chronic Pain Data Research and Development 89

Cannabis Law Report

DECEMBER 11, 2021

The UK’s first and highest-rated medical cannabis clinic, Sapphire Medical Clinics , has today announced that it is reducing the cost of its consultations and appointments for patients enrolled through the Sapphire Access Scheme. The Sapphire Access Scheme will be open to an additional 2,000 patients in the UK.

Access 52

Access Patients Chronic Pain Treatment 52

Veriheal

NOVEMBER 21, 2023

Quemarr’s transformative approach to diabetes treatment offers patients a less intrusive alternative to conventional insulin treatments. The buddie can be paired with a mobile app that tracks consumption, correlating it with health data from devices like WHOOP, Apple Watch, or Fitbit.

Research and Development 106

Research and Development Consumption Education Data 106

NORML

SEPTEMBER 27, 2019

Updated data provided today by the US Centers for Disease Control reports over 800 cases of acute respiratory distress linked to the use of portable vapor cartridges used to consume certain e-liquids. Further information is available from NORML online here , here , and here. percent (36 percent reported exclusive THC-product use); 56.8

Vaping 206

Vaping Data Retail THC 206

Cannabis Chronicles

MAY 22, 2019

SPOKANE — Researchers at Washington State University are teaming up with the Puyallup Tribe of Indians in an effort to chart the tribe’s outcomes prescribing medicinal marijuana to patients. This partnership with WSU and Qwibil will help us research the safety and efficacy of cannabis as medicine for our patients’ use.”.

Medicine 140

Medicine Research and Development Data Collective 140

Cannabis Law Report

SEPTEMBER 1, 2021

WORCESTER —On the eve of Wednesday, September 1, the Cannabis Control Commission (Commission)’s fourth birthday, adult-use Marijuana Establishments in Massachusetts surpassed $2 billion in gross sales , according to information reported in the state’s mandatory seed-to-sale tracking system, the agency announced today.

Marijuana 100

Marijuana Seed-To-Sale Safety Data 100

Cannabis Law Report

JUNE 16, 2021

Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. This engagement will build on the strong foundation on Santé, having treated more than 10,000 patients since 2014 under a real-world data protocol.

Clinical Trials 104

Clinical Trials Therapy Research and Development Events 104

Cannabis Law Report

SEPTEMBER 15, 2021

This deceptive marketing of unproven treatments raises significant public health concerns because patients and other consumers may use them instead of approved therapies to treat serious and even fatal diseases. Of the 22 patients, 19 experienced adverse events after ingesting delta-8 THC-containing food products (e.g.,

THC 105

THC Pets Events Hemp 105

Cannabis Law Report

AUGUST 16, 2022

Seamless data tracking helps operators optimize inventory control, accurately report sales data, and improve cultivation management. We are eager to work side-by-side with the Metrc team to establish a well-regulated supply chain to ensure the long-term safety and security of patients and providers.”.

Seed-To-Sale 52

Seed-To-Sale Supply Chain Data Patients 52

Cannabis Law Report

AUGUST 10, 2021

GW was initially granted marketing authorisation for this medicine in the UK in September 2019 as an adjunctive therapy for seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients two years of age and older. ADDITIONAL INFORMATION.

Pharmaceutical 98

Pharmaceutical Treatment Epilepsy Research and Development 98

Veriheal

AUGUST 3, 2021

Under the terms of the legislation, House Bill 1024 will extend cannabis curbside services and indefinitely eradicate the patient cap for actively serving caregivers. In addition to this, patients will be given the opportunity to acquire a 90-day supply of cannabis. Previously, registered patients were limited to a 30-day supply.

Legislation 98

Legislation Patients Supply Chain Dispensary 98

Cannabis Law Report

JULY 22, 2022

As the only track-and-trace company to have successfully taken over a government contract from another vendor, Metrc will replace the State’s current partner and implement its robust track-and-trace platform to help facilitate the Rhode Island Medical Cannabis Program’s data collection and regulatory oversight. and now Rhode Island.

Data 52

Data Programs Access Compliance 52

Cannabis Law Report

SEPTEMBER 11, 2021

The nature of the position involves designing application receipt and review processes, review of detailed license and renewal applications, preparation of complaints cases for investigations, preparation of investigations cases for disposition, and oversight of vendor data systems for complex laboratory, seed-to-sale tracking, and complaints.

Compliance 105

Compliance Compliance Seed-To-Sale Data 105

Cannabis Law Report

APRIL 5, 2022

Metrc will help facilitate Mississippi’s medical cannabis program’s data collection and regulatory oversight through its robust track-and-trace platform. State regulators can also conveniently access this same information, which will be essential in creating a safe and secure marketplace for both patients and providers. “We

Safety 52

Safety Patients Dispensary Compliance 52

Puff Puff Post

MARCH 10, 2020

InMed has conducted preclinical pharmacology studies that suggest CBN in INM-755 may help relieve hallmark EB symptoms, including inflammation and pain, as well potentially restore the integrity of the skin in a subset of EB Simplex patients. For more information, visit www.inmedpharma.com. Visit [link].

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

MMJ Recs

MARCH 16, 2024

Regulations vary significantly by jurisdiction but typically encompass licensing requirements, product safety standards, and distribution protocols. Key factors influencing market size and revenue include patient demographics, regulatory frameworks, product offerings, and pricing strategies.

Supply Chain 105

Supply Chain Research and Development Marijuana Seed-To-Sale 105

MMJ Recs

NOVEMBER 17, 2023

This article explores the profound impact of MMJ on Maryland communities, shedding light on the medical marijuana benefits experienced by patients and the positive effects it has had on the state’s communities. It has improved the quality of life for those dealing with chronic pain, nausea, seizures, and other medical conditions.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

Veriheal

DECEMBER 23, 2022

Dr. Maxwell’s team also collected data contained in samples sourced from California. After a close analysis of the data, the team determined that an absence of consistent federal guidelines regarding marijuana contaminants ultimately increases the risk of consumers developing health issues.

Research and Development 92

Research and Development Agriculture Data Extraction 92

Cannabis Law Report

JUNE 16, 2021

Genetic Screening Platform Technology and Data to Strengthen Entheon’s Psychedelic-Assisted Protocols. Lobo brings a highly experienced and specialized team of technology experts in the fields of genetics, diagnostics, data and analytics, as well as a fully operational 5,000 sq. Vancouver, British Columbia–(Newsfile Corp.

Research and Development 105

Research and Development Data Conditions Events 105

SpeedWeed

MARCH 6, 2021

Public safety at issue. Proponents of these THC caps—who are often the same politicians who stood against legalization and lost—contend that limiting THC levels will increase public safety. Forcing patients to purchase more. Doing so, Pollara wrote, would effectively force a 50% to 150% tax on patients.

THC 52

THC Patients Law Chronic Pain 52

The Cannigma

JULY 1, 2022

There’s no doubt that the amount of information that is available about cannabis is at an all-time high – in 2020 alone, over 3,500 scientific articles were published on the topic. Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects.

Research and Development 108

Research and Development Data THC Clinical Trials 108

Cannabis Law Report

SEPTEMBER 29, 2021

With more states legalizing cannabis for medical and recreational use, TCI recognizes the critical role that education plays in reducing patient adverse outcomes and ensuring the safe use of cannabis. In addition, Dr. Roberts sees patients at her private practice in Manhattan. TCI was founded by Drs.

Cannabinoids 52

Cannabinoids Education Patients Safety 52

Cannabis Law Report

JUNE 15, 2021

The nature of the position involves designing application receipt and review processes, review of detailed license and renewal applications, preparation of complaints cases for investigations, preparation of investigations cases for disposition, and oversight of vendor data systems for complex laboratory, seed-to-sale tracking, and complaints.

Compliance 105

Compliance Compliance Seed-To-Sale Data 105

Cannabis Law Report

JUNE 5, 2019

The Pharmaceutical Organization, Department of Medical Affairs, signed a joint research on standard quality medical marijuana extracts for patients with chemo-allergic cancer, epilepsy, muscle contraction in patients with deteriorating nerve sheaths. Today (30 May) at 09.30 Effective, most effective in treatment Relieve symptoms.

Pharmaceutical 40

Pharmaceutical Extraction Epilepsy Research and Development 40

Canna Law Blog

APRIL 13, 2019

These products have not been shown to be safe or effective, and deceptive marketing of unproven treatments may keep some patients from accessing appropriate, recognized therapies to treat serious and even fatal diseases.”. Marketing, labeling and sales : How should consumers be informed about the risks associated with such products (e.g.,

CBD 90

CBD Safety Topical Food 90

Cannabis Law Report

JULY 29, 2021

Tetra Bio-Pharma ( TSX: TBP ) ( OTCQB: TBPMF ) ( FRA:JAM1 ) is a leader in cannabinoid-derived drug discovery and development with a FDA and a Health Canada cleared clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. For more information visit: www.tetrabiopharma.com.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105